On April 30, 2025, Hepion Pharmaceuticals, Inc. entered into a binding agreement to in-license diagnostic tests for celiac disease, respiratory multiplex, H. pylori, and liver cancer, committing to pay $525,000 in cash, $200,000 in stock, and up to $17.15 million based on milestones.